Skip to main content

Table 1 B-raf exon 15 mutations in resection specimens of melanoma cutaneous/subcutaneous metastases. Predicted protein sequence alterations are listed together with the clinical course of the disease in patients' follow up. Distinct mutations in two different abnormal bands in SSCP gels are specified by two lines for one melanoma.

From: Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases

Case

Previous primary (months before)

DNA mutations

Predicted Protein changes

Subsequent Metastasis (months later)

1

MM-2.7-IV (30 m)

T1796A

V599E

LN (1 m)

  

g1757A

D586N

 

7

NM-2.5-IV (11 m)

T1796A

V599E

liver (simult)

  

A1810g

S604G

 

12

SSM (18)

T1796A

V599E

liver (74 m)

13

NM-2.1-V (50)

T1796A

V599E

liver (2 m)

20

NM-4-IV (51)

T1796A

V599E

none (74 m)

  

T1837C

S613P

 

22

MM (19)

T1796A

V599E

sc (7 m)

23

MM-1.9-III (37)

g1795A, T1796A

V599K

lung, liver (simult)

24

MM-2.5-IV (84)

T1796A

V599E

bone (simult)

28

no data

g1795A, T1796A

V599K

no follow up

  

C1758A, T1760C, g1795A, T1796A

V599K, L587P

 

29

NM-3.6-IV (13)

g1795A, T1796A

V599K

liver (3 m)

32

no data

g1795A, T1796A

V599K

no follow up

  

g1795A, T1796A, T1803G

V599K

 

34

no data

T1779C, T1796A

F594L, V599E

no follow up

37

SSM-1.8-IV (120)

T1796A

V599E

sc (2 m)

  

T1796A, A1823g

V599E

 

41

MM (144)

T1796A

V599E

lung (simult)

43

SSM-1.8-IV (21)

T1796A

V599E

lung (3 m)

44

MM (71)

T1796A

V599E

lung (simult)

46

LMM-2.7-IV (53)

T1796A

V599E

bone (20 m)

  

g1795A, T1796A

V599K

 

47

MM-1.8-IV (126)

T1796A

V599E

none (42 m)

  

T1787A, T1796A

V599E

 

50

SSM-0.6-III (157)

T1749C, T1796A

V599E

brain, bone (simult)

  

G1824A

WT

 

53

no primary

T1796A

V599E

bone (simult)

  

T1796A, T1847C

V599E, I616T

 

54

LMM-III (290)

T1796A

V599E

sc (8 m)

  

T1796A, A1794T

V599E

 

55

MM-10-V (5)

T1796A, A1830C

V599E, E610D

lung (22 m)

56

MM (1)

T1796A

V599E

lung (1 m)

58

LMM-1.2-V (6)

g1795A, T1796A

V599K

sc (12 m)

  1. Abbreviations used in Table 1: A, adenine; C, cytosine; D, asparagin acid; E, glutamic acid; F, phenylalanine; G, glycine; g, guanine; I, isoleucine; K, lysine; L, leucine; LMM, lentiginous malignant melanoma; LN, lymph node; m, month(s); MM-2.7-IV, melanoma, not further classified, tumour thickness according to Breslow 2.7 mm, Clark's level IV; N, asparagine; NM, nodular melanoma; P, proline; S, serine; sc, subcutaneous; simult, simultaneous; SSM, superficial spreading melanoma; T, thymine; T1857A, change from thymine to adenine at nucleotide 1857 (according to NCBI accession number NM_004333, the start codon ATG corresponding to nucleotide positions 1–3); V, valine; V599E, substitution of valine to glutamic acid at codon 599 (according to NCBI accession number NP_004324.1); WT, wild type of protein sequence.